The sharpest acceleration happened between 2020 and 2022, immediately following the FDA's 2021 approval of semaglutide specifically for weight management
These results indicate that the increased amount of non-12-OH FXR-antagonistic BAs consequent to the decrease in CYP8B1 expression after T3 treatment potentiates GLP-1 production by deactivating the intestinal FXR, thereby improving glucose homeostasis via the augmentation of insulin secretion
At that scale, even a one-unit measurement error represents a 10% dosing mistake
Every review positive or negative remains visible
Similarly, related topics, such as targets for glycemic management [6], glucosemonitoring [7],managementofhypoglycemia [8], and remission of type 2 diabetes [9], are addressed in other chapters
The change weve all been waiting for